二线治疗-话题@MedSci

#二线治疗#

120篇内容 | 3353人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1543987, encodeId=9c0e154398e0a, content=<a href='/topic/show?id=02982402298' target=_blank style='color:#2F92EE;'>#二线治疗#</a>, objectTitle=Target Oncol:真实世界评估阿比特龙+泼尼松或泼尼松龙(AAP)一线或二线治疗转移性去势抵抗前列腺癌(mCRPC)的疗效和安全性, objectType=article, longId=299289, objectId=97bb29928916, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=97bb29928916, replyNumber=0, likeNumber=84, createdTime=2022-02-22, rootId=0, userName=ms5768352621950538, userId=520213623738, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=97bb29928916, moduleTitle=Target Oncol:真实世界评估阿比特龙+泼尼松或泼尼松龙(AAP)一线或二线治疗转移性去势抵抗前列腺癌(mCRPC)的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=97bb29928916)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1543986, encodeId=4206154398672, content=<a href='/topic/show?id=02982402298' target=_blank style='color:#2F92EE;'>#二线治疗#</a>, objectTitle=NEJM：Axicabtagene Ciloleucel作为大B细胞淋巴瘤二线治疗的效果如何？, objectType=article, longId=298992, objectId=90c929899271, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=90c929899271, replyNumber=0, likeNumber=0, createdTime=2022-02-18, rootId=0, userName=ms5768352621950538, userId=520213623738, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=90c929899271, moduleTitle=NEJM：Axicabtagene Ciloleucel作为大B细胞淋巴瘤二线治疗的效果如何？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=90c929899271)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1543985, encodeId=a712154398511, content=<a href='/topic/show?id=02982402298' target=_blank style='color:#2F92EE;'>#二线治疗#</a>, objectTitle=非鳞非小细胞肺癌EGFR阴性脑转移的治疗策略如何？CSCO二线治疗推荐没有免疫联合化疗的推荐, objectType=article, longId=294781, objectId=1a2d294e81fd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1a2d294e81fd, replyNumber=0, likeNumber=80, createdTime=2022-01-28, rootId=0, userName=ms5768352621950538, userId=520213623738, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1a2d294e81fd, moduleTitle=非鳞非小细胞肺癌EGFR阴性脑转移的治疗策略如何？CSCO二线治疗推荐没有免疫联合化疗的推荐, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1a2d294e81fd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1543984, encodeId=6b3b154398477, content=<a href='/topic/show?id=02982402298' target=_blank style='color:#2F92EE;'>#二线治疗#</a>, objectTitle=Lancet Gastroenterol Hepatol：郑大一附院王峰教授CAP 02研究显示卡瑞利珠单抗联合阿帕替尼二线治疗晚期食管鳞癌疗效显著, objectType=article, longId=293995, objectId=58f82939954d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=58f82939954d, replyNumber=0, likeNumber=90, createdTime=2022-01-16, rootId=0, userName=ms5768352621950538, userId=520213623738, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=58f82939954d, moduleTitle=Lancet Gastroenterol Hepatol：郑大一附院王峰教授CAP 02研究显示卡瑞利珠单抗联合阿帕替尼二线治疗晚期食管鳞癌疗效显著, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=58f82939954d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1543983, encodeId=03b41543983ba, content=<a href='/topic/show?id=02982402298' target=_blank style='color:#2F92EE;'>#二线治疗#</a>, objectTitle=Ther Adv Med Oncol：韩国大型真实世界数据评估雷莫芦单抗（Ramucirumab）联合紫杉醇作为二线治疗晚期胃或胃食管交界处腺癌患者的疗效(KCSG-ST19-16), objectType=article, longId=293431, objectId=ec882934312f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ec882934312f, replyNumber=0, likeNumber=77, createdTime=2022-01-06, rootId=0, userName=ms5768352621950538, userId=520213623738, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ec882934312f, moduleTitle=Ther Adv Med Oncol：韩国大型真实世界数据评估雷莫芦单抗（Ramucirumab）联合紫杉醇作为二线治疗晚期胃或胃食管交界处腺癌患者的疗效(KCSG-ST19-16), moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ec882934312f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1543982, encodeId=2aad1543982b8, content=<a href='/topic/show?id=02982402298' target=_blank style='color:#2F92EE;'>#二线治疗#</a>, objectTitle=N Engl J Med：度鲁特韦（Dolutegravir）作为儿童HIV-1感染的一线或二线治疗优于标准治疗, objectType=article, longId=293179, objectId=48b22931e963, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=48b22931e963, replyNumber=0, likeNumber=86, createdTime=2022-01-01, rootId=0, userName=ms5768352621950538, userId=520213623738, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=48b22931e963, moduleTitle=N Engl J Med：度鲁特韦（Dolutegravir）作为儿童HIV-1感染的一线或二线治疗优于标准治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=48b22931e963)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1543980, encodeId=dee315439805a, content=<a href='/topic/show?id=02982402298' target=_blank style='color:#2F92EE;'>#二线治疗#</a>, objectTitle=NEJM：多替拉韦作为HIV-1感染儿童的一线或二线治疗, objectType=article, longId=293165, objectId=0a93293165a8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0a93293165a8, replyNumber=0, likeNumber=90, createdTime=2021-12-31, rootId=0, userName=ms5768352621950538, userId=520213623738, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0a93293165a8, moduleTitle=NEJM：多替拉韦作为HIV-1感染儿童的一线或二线治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0a93293165a8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1543981, encodeId=dfa815439818e, content=<a href='/topic/show?id=02982402298' target=_blank style='color:#2F92EE;'>#二线治疗#</a>, objectTitle=Signal Transduct Target Ther：PD-1抑制剂Toripalimab（特瑞普利单抗）联合化疗二线治疗晚期EGFR突变NSCLC一线TKI进展后显示良好抗肿瘤疗效和可控安全性, objectType=article, longId=293109, objectId=d234293109ad, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d234293109ad, replyNumber=0, likeNumber=55, createdTime=2021-12-31, rootId=0, userName=ms5768352621950538, userId=520213623738, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d234293109ad, moduleTitle=Signal Transduct Target Ther：PD-1抑制剂Toripalimab（特瑞普利单抗）联合化疗二线治疗晚期EGFR突变NSCLC一线TKI进展后显示良好抗肿瘤疗效和可控安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d234293109ad)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1543979, encodeId=a83c15439e992, content=<a href='/topic/show?id=02982402298' target=_blank style='color:#2F92EE;'>#二线治疗#</a>, objectTitle=J Clin Oncol：PD-1和CTLA-4双重阻断二线治疗晚期宫颈癌疗效显著, objectType=article, longId=292558, objectId=2c632925589c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2c632925589c, replyNumber=0, likeNumber=86, createdTime=2021-12-24, rootId=0, userName=ms5768352621950538, userId=520213623738, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2c632925589c, moduleTitle=J Clin Oncol：PD-1和CTLA-4双重阻断二线治疗晚期宫颈癌疗效显著, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2c632925589c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1543978, encodeId=ef2815439e86e, content=<a href='/topic/show?id=02982402298' target=_blank style='color:#2F92EE;'>#二线治疗#</a>, objectTitle=Clin Cancer Res：PARP抑制剂Veliparib联合优化的FOLFIRI作为二线治疗转移性胰腺癌, objectType=article, longId=221813, objectId=789422181362, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=789422181362, replyNumber=0, likeNumber=105, createdTime=2021-12-11, rootId=0, userName=ms5768352621950538, userId=520213623738, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=789422181362, moduleTitle=Clin Cancer Res：PARP抑制剂Veliparib联合优化的FOLFIRI作为二线治疗转移性胰腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=789422181362)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1543976, encodeId=982815439e656, content=<a href='/topic/show?id=02982402298' target=_blank style='color:#2F92EE;'>#二线治疗#</a>, objectTitle=阿帕替尼二线治疗晚期胃腺癌的病例一例, objectType=article, longId=221350, objectId=23ea221350b4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=23ea221350b4, replyNumber=0, likeNumber=61, createdTime=2021-12-02, rootId=0, userName=ms5768352621950538, userId=520213623738, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=23ea221350b4, moduleTitle=阿帕替尼二线治疗晚期胃腺癌的病例一例, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=23ea221350b4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1543977, encodeId=d56a15439e7ee, content=<a href='/topic/show?id=02982402298' target=_blank style='color:#2F92EE;'>#二线治疗#</a>, objectTitle=Leuk Lymphoma：帕纳替尼与其他酪氨酸激酶抑制剂作为美国慢性粒细胞白血病患者二线治疗的安全性和成本效益, objectType=article, longId=221252, objectId=69a622125247, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=69a622125247, replyNumber=0, likeNumber=45, createdTime=2021-12-01, rootId=0, userName=ms5768352621950538, userId=520213623738, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=69a622125247, moduleTitle=Leuk Lymphoma：帕纳替尼与其他酪氨酸激酶抑制剂作为美国慢性粒细胞白血病患者二线治疗的安全性和成本效益, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=69a622125247)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1543975, encodeId=ddde15439e52e, content=<a href='/topic/show?id=02982402298' target=_blank style='color:#2F92EE;'>#二线治疗#</a>, objectTitle=Liver Cancer：Atezolizumab (ATEZO) + bevacizumab (BEVA)一线治疗晚期HCC进展后，二线治疗选择对比, objectType=article, longId=221201, objectId=587522120103, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=587522120103, replyNumber=0, likeNumber=67, createdTime=2021-11-30, rootId=0, userName=ms5768352621950538, userId=520213623738, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=587522120103, moduleTitle=Liver Cancer：Atezolizumab (ATEZO) + bevacizumab (BEVA)一线治疗晚期HCC进展后，二线治疗选择对比, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=587522120103)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1543974, encodeId=4c0a15439e4e1, content=<a href='/topic/show?id=02982402298' target=_blank style='color:#2F92EE;'>#二线治疗#</a>, objectTitle=Eur J Haematol：多发性骨髓瘤对一线和二线治疗的反应动力学, objectType=article, longId=221129, objectId=a724221129f9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a724221129f9, replyNumber=0, likeNumber=104, createdTime=2021-11-28, rootId=0, userName=ms5768352621950538, userId=520213623738, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a724221129f9, moduleTitle=Eur J Haematol：多发性骨髓瘤对一线和二线治疗的反应动力学, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a724221129f9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1543973, encodeId=bcd915439e338, content=<a href='/topic/show?id=02982402298' target=_blank style='color:#2F92EE;'>#二线治疗#</a>, objectTitle=Thorac Cancer：回顾性分析多西他赛联合雷莫芦单抗（ramucirumab）二线治疗化疗联合免疫治疗进展的晚期NSCLC患者的疗效, objectType=article, longId=220896, objectId=74f1220896c6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=74f1220896c6, replyNumber=0, likeNumber=108, createdTime=2021-11-25, rootId=0, userName=ms5768352621950538, userId=520213623738, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=74f1220896c6, moduleTitle=Thorac Cancer：回顾性分析多西他赛联合雷莫芦单抗（ramucirumab）二线治疗化疗联合免疫治疗进展的晚期NSCLC患者的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=74f1220896c6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1543972, encodeId=b05315439e29f, content=<a href='/topic/show?id=02982402298' target=_blank style='color:#2F92EE;'>#二线治疗#</a>, objectTitle=Front Oncol：晚期胆管癌一线和二线治疗疗效，以及剂量下调时对疗效影响 , objectType=article, longId=220211, objectId=7218220211e4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7218220211e4, replyNumber=0, likeNumber=77, createdTime=2021-11-13, rootId=0, userName=ms5768352621950538, userId=520213623738, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7218220211e4, moduleTitle=Front Oncol：晚期胆管癌一线和二线治疗疗效，以及剂量下调时对疗效影响 , moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7218220211e4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1543971, encodeId=cd5515439e174, content=<a href='/topic/show?id=02982402298' target=_blank style='color:#2F92EE;'>#二线治疗#</a>, objectTitle=Clin Cancer Res：托瑞帕利单抗二线治疗转移性尿路上皮癌的疗效、安全性和生物标志物, objectType=article, longId=220114, objectId=de3b22011460, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=de3b22011460, replyNumber=0, likeNumber=73, createdTime=2021-11-12, rootId=0, userName=ms5768352621950538, userId=520213623738, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=de3b22011460, moduleTitle=Clin Cancer Res：托瑞帕利单抗二线治疗转移性尿路上皮癌的疗效、安全性和生物标志物, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=de3b22011460)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1543970, encodeId=5f1d15439e096, content=<a href='/topic/show?id=02982402298' target=_blank style='color:#2F92EE;'>#二线治疗#</a>, objectTitle=Blood Cells Mol Dis：艾曲波帕作为原发性免疫性血小板减少症患者二线治疗的有效性和安全性, objectType=article, longId=219573, objectId=1bc72195e3c8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1bc72195e3c8, replyNumber=0, likeNumber=102, createdTime=2021-11-02, rootId=0, userName=ms5768352621950538, userId=520213623738, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1bc72195e3c8, moduleTitle=Blood Cells Mol Dis：艾曲波帕作为原发性免疫性血小板减少症患者二线治疗的有效性和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1bc72195e3c8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1543969, encodeId=73611543969e3, content=<a href='/topic/show?id=02982402298' target=_blank style='color:#2F92EE;'>#二线治疗#</a>, objectTitle=Lancet子刊：雷莫芦单抗联合紫杉醇可作为中国晚期胃癌或GEJ腺癌患者的二线治疗！, objectType=article, longId=218209, objectId=f08c2182095b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f08c2182095b, replyNumber=0, likeNumber=87, createdTime=2021-10-09, rootId=0, userName=智者为医08, userId=4dfa37, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f08c2182095b, moduleTitle=Lancet子刊：雷莫芦单抗联合紫杉醇可作为中国晚期胃癌或GEJ腺癌患者的二线治疗！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f08c2182095b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1543968, encodeId=f869154396857, content=<a href='/topic/show?id=02982402298' target=_blank style='color:#2F92EE;'>#二线治疗#</a>, objectTitle=JNCCN：真实世界研究中转移性胰腺癌患者一线和二线治疗的预后, objectType=article, longId=216799, objectId=0e7f216e9991, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0e7f216e9991, replyNumber=0, likeNumber=66, createdTime=2021-09-09, rootId=0, userName=智者为医08, userId=4dfa37, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0e7f216e9991, moduleTitle=JNCCN：真实世界研究中转移性胰腺癌患者一线和二线治疗的预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0e7f216e9991)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

二线治疗

2020-05-29

ms5768352621950538 (审核中...)

前往app查看评论内容

#二线治疗#

Target Oncol:真实世界评估阿比特龙+泼尼松或泼尼松龙(AAP)一线或二线治疗转移性去势抵抗前列腺癌(mCRPC)的疗效和安全性

2022-02-22

ms5768352621950538 (审核中...)

前往app查看评论内容

#二线治疗#

NEJM：Axicabtagene Ciloleucel作为大B细胞淋巴瘤二线治疗的效果如何？

2022-02-18

ms5768352621950538 (审核中...)

前往app查看评论内容

#二线治疗#

非鳞非小细胞肺癌EGFR阴性脑转移的治疗策略如何？CSCO二线治疗推荐没有免疫联合化疗的推荐

2022-01-28

ms5768352621950538 (审核中...)

前往app查看评论内容

#二线治疗#

Lancet Gastroenterol Hepatol：郑大一附院王峰教授CAP 02研究显示卡瑞利珠单抗联合阿帕替尼二线治疗晚期食管鳞癌疗效显著

2022-01-16

ms5768352621950538 (审核中...)

前往app查看评论内容

#二线治疗#

Ther Adv Med Oncol：韩国大型真实世界数据评估雷莫芦单抗（Ramucirumab）联合紫杉醇作为二线治疗晚期胃或胃食管交界处腺癌患者的疗效(KCSG-ST19-16)

2022-01-06

ms5768352621950538 (审核中...)

前往app查看评论内容

#二线治疗#

N Engl J Med：度鲁特韦（Dolutegravir）作为儿童HIV-1感染的一线或二线治疗优于标准治疗

2022-01-01

ms5768352621950538 (审核中...)

前往app查看评论内容

#二线治疗#

NEJM：多替拉韦作为HIV-1感染儿童的一线或二线治疗

2021-12-31

ms5768352621950538 (审核中...)

前往app查看评论内容

#二线治疗#

Signal Transduct Target Ther：PD-1抑制剂Toripalimab（特瑞普利单抗）联合化疗二线治疗晚期EGFR突变NSCLC一线TKI进展后显示良好抗肿瘤疗效和可控安全性

2021-12-31

ms5768352621950538 (审核中...)

前往app查看评论内容

#二线治疗#

J Clin Oncol：PD-1和CTLA-4双重阻断二线治疗晚期宫颈癌疗效显著

2021-12-24

ms5768352621950538 (审核中...)

前往app查看评论内容

#二线治疗#

Clin Cancer Res：PARP抑制剂Veliparib联合优化的FOLFIRI作为二线治疗转移性胰腺癌

2021-12-11

ms5768352621950538 (审核中...)

前往app查看评论内容

#二线治疗#

阿帕替尼二线治疗晚期胃腺癌的病例一例

2021-12-02

ms5768352621950538 (审核中...)

前往app查看评论内容

#二线治疗#

Leuk Lymphoma：帕纳替尼与其他酪氨酸激酶抑制剂作为美国慢性粒细胞白血病患者二线治疗的安全性和成本效益

2021-12-01

ms5768352621950538 (审核中...)

前往app查看评论内容

#二线治疗#

Liver Cancer：Atezolizumab (ATEZO) + bevacizumab (BEVA)一线治疗晚期HCC进展后，二线治疗选择对比

2021-11-30

ms5768352621950538 (审核中...)

前往app查看评论内容

#二线治疗#

Eur J Haematol：多发性骨髓瘤对一线和二线治疗的反应动力学

2021-11-28

ms5768352621950538 (审核中...)

前往app查看评论内容

#二线治疗#

Thorac Cancer：回顾性分析多西他赛联合雷莫芦单抗（ramucirumab）二线治疗化疗联合免疫治疗进展的晚期NSCLC患者的疗效

2021-11-25

ms5768352621950538 (审核中...)

前往app查看评论内容

#二线治疗#

Front Oncol：晚期胆管癌一线和二线治疗疗效，以及剂量下调时对疗效影响

2021-11-13

ms5768352621950538 (审核中...)

前往app查看评论内容

#二线治疗#

Clin Cancer Res：托瑞帕利单抗二线治疗转移性尿路上皮癌的疗效、安全性和生物标志物

2021-11-12

ms5768352621950538 (审核中...)

前往app查看评论内容

#二线治疗#

Blood Cells Mol Dis：艾曲波帕作为原发性免疫性血小板减少症患者二线治疗的有效性和安全性

2021-11-02

智者为医08 (审核中...)

前往app查看评论内容

#二线治疗#

Lancet子刊：雷莫芦单抗联合紫杉醇可作为中国晚期胃癌或GEJ腺癌患者的二线治疗！

2021-10-09

智者为医08 (审核中...)

前往app查看评论内容

#二线治疗#

JNCCN：真实世界研究中转移性胰腺癌患者一线和二线治疗的预后

2021-09-09

科室
- - 订阅+
  - 更多科室
工具
服务